In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now

Executive Summary

Sanofi-Aventis' much publicized pursuit - first hostile, then friendly - of Genzyme dominated biopharma news flow for more than half a year, with well timed information leaks and dramatic "he said, he said" commentary from the firms' CEOs. Such back and forth ensured continued high profile coverage until the companies officially affianced. But beyond the drama, the $20.1 billion deal, among the largest since the 2009 mega-mergers between Pfizer and Wyeth and Merck & Co. and Schering-Plough Corp., is worth discussion because it provides insight into what now drives big pharma dealmaking in the post-blockbuster era - and how companies want to pay for it.
Advertisement

Related Content

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need
Celgene Flexes Its Muscles
A Look Back At 2010: In Search Of New Biopharma Models
Pharma: Serious About Change?
Bristol-Myers Squibb and Otsuka Stabilize Their Bases
Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED
Shire: Remodeling Specialty Pharma
Shire: Remodeling Specialty Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel